Veracyte Inc. is a leading biotechnology company focused on advancing genomic medicine to improve patient care in oncology and other diseases
The company specializes in developing innovative diagnostic solutions that enhance the accuracy of clinical decision-making, particularly in the evaluation of thyroid nodules, lung cancer, and other conditions where traditional tissue biopsy can be inconclusive or invasive. By leveraging advanced genomic technology and a platform of proprietary tests, Veracyte aims to provide physicians and patients with reliable information that can inform treatment choices and ultimately lead to better outcomes in personalized medicine.
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data that reinforce the ability of its Decipher Bladder Genomic Subtyping Classifier to help improve staging for patients with bladder cancer, based on their tumors’ molecular subtype. The findings, published in European Urology Open Science, show that the test can help clinicians better determine which patients are more likely to harbor more aggressive disease than suggested by their initial clinical staging following transurethral resection of bladder tumor (TURBT).
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2024 after the close of market on Monday, February 24, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the only gene expression test to be included in version 1 of the 2025 NCCN* Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as part of the updated “Advanced Tools” table located in the Principles of Risk Stratification and Biomarkers section (PROS-H) .
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2024 after the close of market on Wednesday, November 6, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new data from the multicenter, prospective VANDAAM trial show that the Decipher Prostate Genomic Classifier accurately predicts aggressive prostate cancer among African American men with early-stage disease. The findings confirm that the market-leading genomic test offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions for African American men, a population that is disproportionately impacted by the disease. The new data were shared today in an oral presentation at ASTRO 2024, the annual meeting of the American Society for Radiation Oncology, in Washington, D.C.
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data from a phase 3 trial of the multi-center, randomized STAMPEDE clinical trial show that its Decipher Prostate Genomic Classifier is prognostic for clinical outcomes and predicts benefit from docetaxel in patients with metastatic prostate cancer. The findings were presented today (Presentation #15960) at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona. These findings support Veracyte’s plan to expand use of the Decipher Prostate test – currently widely used to guide care for localized prostate cancer – to patients with metastatic disease.
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.
Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 2:35 p.m. Eastern Time.
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that it has been named a Bay Area Top Workplace by the San Francisco Chronicle. The award marks the 11th consecutive year that Veracyte has received this honor.
Veracyte reports Q2 sales of $114.43M, a 27% increase year over year, surpassing the $100.3 million consensus. Testing revenue rose 31% to $107 million, driven by strong performance of Decipher Prostate and Afirma tests. Adjusted EPS was $0.30, beating expectations.
